Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
 |
New Vision (Kampala) - August 26, 2007
Denis Ocwich
The five-year research, funded by the American National Institute of Allergy and Infectious Diseases, will bring together an international consortium of physician and research scientists from South Africa, Brazil, Philippines, Uganda and the US.
According to a statement from Case Western Reserve University, the $27m award followed an earlier $28m for a seven-year TB research which started in 1999.
Uganda, which is ranked 15th among the 22 tuberculosis-endemic countries, also partook of the first phase.
Henry Boom, the principal investigator and professor of Medicine at the School of Medicine and University Hospitals, Case Medical Centre, said the Uganda-Case Research Collaboration, involving medics and researchers from Makerere University, Mulago Hospital and the Joint Clinical Research Centre (JCRC) will "feature prominently" in the project.
The research, which will look at the immune response to TB and why some people easily develop active TB, will be led by the TB Research Unit of Case Western Reserve University's School of Medicine in Ohio, USA.
It will investigate why the TB vaccine that is used worldwide to protect newborn and young children is no longer protecting adolescents and adults from TB.
Since 1962, no new TB drug has been developed. Under the Global Plan to Stop TB, launched in 2000, there has been renewed vigour (socially and politically) to rid the world of TB, which kills nearly two million people and infects nine million others every year.
It is projected that the first new TB drug in 40 years will be introduced in 2010. The drug is hoped to entail a much faster TB regiment (lasting one to two months, compared with the current six to eight months).
The current TB dosage (first-line treatment) entails a combination of four tablets ù Rifampicin, Isoniazid, Pyrazinamide and Ethambutol. In Uganda, the studies will address the growing problem of HIV-TB co-infection, said Dr. Peter Mugyenyi, the director of JCRC.
He said the Uganda National Tuberculosis and Leprosy Programme calculates that HIV has led to a four-fold increase in TB cases in the country.
The use of anti-retroviral therapy (ART) in HIV-positive patients is responsible for a new phenomenon called ART-induced Immune Reconstitution Inflammatory Syndrome, which leads to high death rates among people who have just started taking ARVs.
"TB increases the speed of HIV, and HIV increases the speed of TB," Mugyenyi said, adding that: "TB which is latent can easily flare up once an HIV-infected person starts taking ARVs."
070826
NV070825
Copyright © 2007 - The New Vision. All articles are republished on AEGIS by permission. Material may not be redistributed, posted to any other location, published or used for broadcast without written authorization from Managing Director/Editor-in-chief, The New Vision, P.O. Box 9815, Kampala - Uganda, Tel/fax: 256-41-235221, E-mail: wpike@newvision.co.ug.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .